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gnomonic to liver cirrhosis, the term ‘cirrhosis-associated’ may
be a more adequate term than ‘cirrhotic’ cardiomyopathy.
In summary, cardiac dysfunction in cirrhosis may not only be
stress-related. There is a need to apply new technology in
exploring more sensitive markers of left ventricular dysfunction
in cirrhosis. Equally important, there is a need to explore the
role of other chambers of the heart, such as the right ventricle,
in the characterization and prognosis of cirrhosis-associated
cardiomyopathy.
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JOURNAL OF HEPATOLOGYVitamin D status does not predict sustained virologic response or
ﬁbrosis stage in chronic hepatitis C genotype 1 infectionTo the Editor:
In their recent study published in the Journal of Hepatology,
Kitson et al. report that vitamin D status does not predict sus-
tained virologic response (SVR) in genotype 1 chronic hepatitis
C patients [1]. Their ﬁndings are consistent with those of another
group [2], but in contrast to the ﬁndings of several other studies,
in which a correlation between the serum 25-hydroxyvitamin D
[25(OH)D] level and rate of attaining an SVR was identiﬁed
[3–7]. Kitson et al. argue for the strength of their conclusion
and suggest that the correlation between 25(OH)D level and
SVR identiﬁed in the other studies was secondary to confounding
effects. They thereby imply that the 25(OH)D level is not a
determinant of treatment outcome. However, they do not address
the signiﬁcant evidence, from clinical, genetic, animal, and cell
culture studies, that supports a role for endogenous vitamin D
in the treatment response [8]. In light of this evidence, it would
have been prudent for Kitson et al. to have explored the possibil-
ity that certain aspects of their study may have obscured
evidence of a functional relationship between 25(OH)D level
and response to treatment.
For example, whereas all of the study populations, in which a
correlation between 25(OH)D level and the rate of SVR was iden-
tiﬁed, were racially homogeneous, the patients in the Kitson et al.
study were racially diverse. This is of potential consequence in
that there is increasing evidence that there are clinically signiﬁ-
cant racial differences in vitamin D physiology and some of these
may affect genotype 1 chronic hepatitis C treatment outcome
(discussed in [7]). In this regard, it is notable that the Asian
patients in the Kitson et al. study had lower levels of 25(OH)D,
but a higher rate of SVR than the study group as a whole – it is
possible that the level of 25(OH)D necessary for an optimal treat-
ment response is lower in Asians when compared to levels
required for an optimal treatment response in other groups. This
would have attenuated a correlation between 25(OH)D levels and
rate of SVR when their entire group of patients was analyzed
together.
Indeed, there is tangible evidence that there are quantitative
differences in the relationship between 25(OH)D and the
response to genotype 1 chronic hepatitis C treatment outcome
between individual patients. There are alleles of single nucleotide
polymorphisms (SNPs) in two different genes in the vitamin D
metabolic pathway that increase the physiologic effects of
25(OH)D and these same alleles are also associated with an
improved rate of SVR [2,6,9]. This suggests that there is a func-
tional relationship between 25(OH)D level and treatment
response in genotype 1 chronic hepatitis C patients. However,
because the alleles of these SNPs vary between individual
patients, this relationship would be quantitatively different from
patient to patient, such that a correlation may not be evident
when the relationship between 25(OH)D level and SVR is evalu-
ated among a group of patients.
Another characteristic of their study that could have weak-
ened a correlation between 25(OH)D level and treatment
response is the liquid chromatography–tandem mass spectrome-Journal of Hepatology 2013 vol. 59 j 190–199 193
try methodology that they used to measure 25(OH)D. This assay
does not distinguish between 25(OH)D and an epimer of 25(OH)D
that is present in variable amounts in most adults, with levels of
the epimer exceeding 7.5 nmol/L in 8% of the adults in one large
study [10]. The epimer binds to the vitamin D receptor, but it
lacks many of the activities of vitamin D [10], so it is likely that
the epimer acts as a competitive inhibitor for some of the activ-
ities of vitamin D. Therefore, the differences in the relationship
between the measured 25(OH)D level [i.e., 25(OH)D plus epimer]
and the actual 25(OH)D level could have compromised the con-
clusions of their study. In contrast, most of the studies, in which
a correlation between 25(OH)D level and the rate of SVR was
identiﬁed, used a 25(OH)D assay that is unaffected by the epimer
[4–7,10].
Considering the variation in vitamin D physiology between
patients and the complexity of measuring vitamin D levels, a lack
of a correlation between 25(OH)D level and the rate of SVR
among a group of patients should not be interpreted as a lack
of importance of vitamin D status in genotype 1 chronic hepatitis
C treatment outcome. In the context of the evidence that vitamin
D has a functional role as a determinant treatment response [8], it
is important to consider the possibility that the level of 25(OH)D
may be important in the response to treatment of an individual
genotype 1 chronic hepatitis C patient, but that this may not be
apparent when the relationship between 25(OH)D level and the
rate of attaining an SVR is analyzed among a group of patients.
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Reply to: ‘‘Vitamin D status does not predict sustained virologic
response or ﬁbrosis stage in chronic hepatitis C genotype 1 infection’’
To the Editor:
We thank Dr. Weintraub for his in-depth analysis of our paper
and the insightful questions he has raised. Our study of 274
patients showing no independent association between baseline
25-hydroxyvitamin D [25(OH)D] status and sustained virologic
response (SVR) in chronic hepatitis C genotype 1 (HCV-1) infec-
tion [1] was similar to 3 other published studies [2–4] involving
765 patients with HCV-1. Notably, published studies with the
contrary ﬁnding of an association between baseline 25(OH)D
level and SVR in HCV-1 have involved only 448 patients in total,
with the largest including 171 patients.
Ethnic variation is one potential explanation for the differ-
ences observed between studies to date. However, in a further
analysis of the sub-cohort of 234 Caucasian patients in our study,
we found the results of multivariate analysis did not change.
Moreover, the univariate association found between lower
25(OH)D level and SVR in the entire cohort lost statistical signif-
icance. This is not surprising as the Asian population (n = 34) in
our study had a lower 25(OH)D level but a higher prevalence of
rs12979860 interleukin-28B (IL28B) CC genotype. Indeed, our
study found a trend association between IL28B CC genotype and
lower 25(OH)D level.
Our study only comments on baseline 25(OH)D status and
SVR and does not address whether the in vitro antiviral effect of
vitamin D in HCV infection translates to improved treatment out-
comes to PegIFN-based antiviral therapy in HCV-1. This question
is best addressed by a randomized, placebo-controlled clinical
trial. Unfortunately, this data is lacking and the few prospective
studies on vitamin D supplementation are small and do not
involve a placebo-control arm [5,6]. Any further studies address-
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